Annexon Biosciences

Contributing Author

Recent Articles by Annexon Biosciences

Jul-16	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) ANNX -9.38% GlobeNewswire
Jul-14	Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026 ANNX ANNX +17.12% GlobeNewswire
Jun-16	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) ANNX ANNX +9.29% GlobeNewswire
May-27	Annexon to Participate in Upcoming June Investor Conferences ANNX GlobeNewswire
May-18	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) ANNX GlobeNewswire
May-07	Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones ANNX GlobeNewswire
May-06	Annexon to Present at the Bank of America Securities Health Care Conference 2026 ANNX GlobeNewswire
Apr-08	Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference ANNX GlobeNewswire
Mar-30	Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones ANNX ANNX +11.69% GlobeNewswire
Mar-16	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) ANNX GlobeNewswire
Feb-24	Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference ANNX GlobeNewswire
Feb-17	Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy ANNX GlobeNewswire
Jan-16	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) ANNX GlobeNewswire
Jan-12	Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 ANNX +5.90% GlobeNewswire
Jan-08	Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barre Syndrome ANNX GlobeNewswire
Jan-07	Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference ANNX +8.43% GlobeNewswire
Dec-16	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) ANNX GlobeNewswire
Nov-14	Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million ANNX ANNX +11.44% GlobeNewswire
Nov-12	Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants ANNX -5.63% GlobeNewswire
Nov-12	Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants ANNX ANNX -5.63% GlobeNewswire
Nov-10	Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones ANNX GlobeNewswire
Aug-27	Annexon Biosciences to Participate in Upcoming September Investor Conferences ANNX GlobeNewswire
Aug-18	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) ANNX ANNX -6.81% GlobeNewswire
Aug-14	Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones ANNX -8.46% GlobeNewswire
Aug-07	Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy ANNX GlobeNewswire
Jul-24	Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy ANNX GlobeNewswire
Jun-18	Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) ANNX GlobeNewswire
May-29	Annexon Biosciences to Present at the Jefferies Global Healthcare Conference ANNX +7.39% ANNX -6.42% GlobeNewswire
May-19	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barre Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting ANNX GlobeNewswire
May-16	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) ANNX +11.05% GlobeNewswire
May-12	Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones ANNX +10.62% GlobeNewswire
May-09	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) at the 2025 PNS Meeting ANNX -5.88% GlobeNewswire
May-07	Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress ANNX GlobeNewswire

Annexon Biosciences

Recent Articles by Annexon Biosciences

Upgrade your Finviz experience